Makers Laboratories share price
NSE: MAKERSLBSE: 506919Pharmaceuticals & BiotechnologySmall Cap
Last close ₹187.02down ₹11.64 (5.86%)BSE ₹192.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹198.66.
52-week range of BSE trades to 23 Oct 2026
₹109.00Low, 22 Dec 2025₹239.00High, 21 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: quarterly results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹110 Cr3,027th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 7 Aug 2026
- 32.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 1.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 7 Aug 2026
- 4.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Aug 2026
- 11.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.04
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 4,74377.2% delivered
Results
Standalone, as consolidated accounts are on record for only 6 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 7 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹10 Crdown 9.64%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹1.08 CrQuarter to Mar 2026: −₹0.96 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −10.6%
Revenue by year
Peak revenue ₹59 Cr, year to Mar 2017
Net profit by year, a loss in red
- Net profit
- Loss
A loss in the year to Mar 2026, −₹1.72 CrA loss in 5 of the 10 years shown
| ₹ crore | Sep 2024Filed 30 Oct | Dec 2024Filed 29 Jan | Mar 2025Filed 12 Jun | Jun 2025Filed 8 Aug | Sep 2025Filed 7 Nov | Dec 2025Filed 10 Feb | Mar 2026Filed 26 May | Jun 2026Filed 7 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.5 | 9.5 | 9.7 | 13.7 | 12.6 | 12.7 | 11.3 | 10.2 |
| Net profit | 8.0 | −0.8 | −1.4 | −0.3 | −0.3 | −0.2 | −1.0 | −1.1 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 69.8% | −8.2% | −14.5% | −2.0% | −2.5% | −1.4% | −8.5% | −10.6% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- Chemical ManufacturingChemical Manufacturing, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹91.9 Crup 16.63%64.6%
- PharmaceuticalPharmaceutical, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹50.4 Crdown 6.38%35.4%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 24% of 182 trading days over the last year.
LowestHighest
Its median38.1Industry median28.1
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 79% of 1,846 trading days since Nov 2018.
LowestHighest
Its median1.2Industry median2.9
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.6.1
At or below today's level on 10% of 1,830 trading days since Nov 2018.
LowestHighest
Its median14.5Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 63% of 2,456 trading days over the last 10 years.
LowestHighest
Its median0.00%Industry median0.53%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +4.8% | – | – | 0.0% |
| 3 years | +11.5% | – | – | 0.0% |
| 5 years | −10.8% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Makers Laboratories in market cap. 1 company in the table last traded before then: its row is priced on its last trade.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Himalaya Nutravedics IndiaHNIL | 121 | – | – | – | – | – | – | – | 0.00% |
 Parnax LabPARNAXLAB | 119 | 13.3 | 1.2 | 7.9 | +31.9% | −17.3% | 10.0% | 9.3% | 0.00% |
 BALAXI PHARMACEUTICALSBALAXI | 115 | 47.6 | 0.5 | 17.3 | −5.9% | −87.2% | 1.0% | 2.1% | 0.00% |
 Krebs Biochemicals and IndustriesKREBSBIO | 112 | – | – | – | −29.7% | – | – | −14.4% | 0.00% |
 Tyche IndustriesTYCHE | 107 | 24.0 | 0.8 | – | −21.0% | −63.5% | 3.2% | −2.5% | 3.36% |
 Alpa LaboratoriesALPA | 104 | – | 0.6 | – | +0.5% | – | – | −1.8% | 0.00% |
 Pharmaids PharmaceuticalsPHARMAID | 102 | – | 2.1 | – | +18.5% | – | −8.5% | −15.8% | 0.00% |
 Sotac PharmaceuticalsSOTAC | 102 | 17.6 | 1.7 | – | +0.1% | −28.2% | 10.3% | – | 0.22% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹1.00 a share, years to Mar 2017, Mar 2018 and Mar 2019.
| Ex-date | Type | Per share |
|---|---|---|
| 1 Aug 2019 | Final | ₹1.00 |
| 26 Jul 2018 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.00 |
| 20 Jul 2017 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.00 |
| 2 Aug 2016 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.00 |
| 28 Jul 2015 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.00 |
| 29 Jul 2011 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
21 Oct · Board meeting
Meeting on 4 Nov 2026: quarterly results19 Oct · Meeting
Sep 2026
1 Sep · Rating
Makers Laboratories share price by year
Each calendar year to 2025.Makers Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 118.15 | −34.4% | 219.10 | 112.05 |
| 2024BSE close | 180.20 | +30.0% | 180.20 | 111.55 |
| 2023BSE close | 138.60 | +14.4% | 147.70 | 97.65 |
| 2022BSE close | 121.15 | −38.0% | 217.20 | 117.10 |
| 2021BSE close | 195.45 | −37.1% | 334.85 | 187.10 |
| 2020BSE close | 310.75 | +696.8% | 310.75 | 25.95 |
| 2019BSE close | 39.00 | −43.6% | 69.10 | 33.00 |
| 2018BSE close | 69.15 | −36.1% | 109.30 | 63.55 |
| 2017BSE close | 108.30 | +15.6% | 135.60 | 73.55 |
| 2016BSE close | 93.70 | −2.4% | 107.30 | 59.30 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 190.50 | 195.00 | 181.00 | 187.02 | 187.33 | 4,743 | 77.2% |
| 22 Oct 2026 | 207.00 | 207.00 | 191.00 | 198.66 | 195.58 | 1,668 | 66.1% |
| 21 Oct 2026 | 213.00 | 214.95 | 191.01 | 198.00 | 199.15 | 2,997 | 85.7% |
| 19 Oct 2026 | 212.50 | 215.00 | 202.00 | 208.99 | 210.43 | 3,826 | 79.6% |
| 16 Oct 2026 | 199.09 | 212.90 | 196.12 | 208.11 | 207.84 | 7,705 | 63.4% |
| 15 Oct 2026 | 200.10 | 209.00 | 199.00 | 203.15 | 205.19 | 5,427 | 71.5% |
| 14 Oct 2026 | 196.00 | 200.00 | 191.00 | 199.21 | 198.12 | 2,873 | 81.8% |
| 13 Oct 2026 | 192.90 | 205.00 | 187.01 | 188.98 | 198.99 | 16,939 | 76.6% |
| 12 Oct 2026 | 178.00 | 201.40 | 178.00 | 187.00 | 190.85 | 5,048 | 67.2% |
| 9 Oct 2026 | 179.50 | 180.50 | 177.00 | 177.07 | 179.79 | 2,971 | 98.5% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Rights issue history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 30 Mar 2022 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
Each event is noted and not adjusted for.
Company details
- Legal name
- Makers Laboratories Limited
- NSE symbol
- MAKERSL
- BSE code
- 506919
- ISIN
- INE987A01010
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Nov 1985
- Face value
- ₹10
- CIN
- L24230MH1984PLC033389
- Corporate identity number, the registrar of companies' code for it